DeCure for Spondyloepiphyseal dysplasia with congenital joint dislocations
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for spondyloepiphyseal dysplasia with congenital joint dislocations — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSpondyloepiphyseal dysplasia with congenital joint dislocations maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for spondyloepiphyseal dysplasia with congenital joint dislocations is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Spondyloepiphyseal dysplasia with congenital joint dislocations (SDCD) overlaps genetically with Desbuquois dysplasia (DD). In a 2012 study of 38 DD cases (6 type 1, 1 Kim variant, 31 type 2), mutations in CANT1 were found in all DD type 1 cases, the Kim variant, and one atypical DD type 2. One DD type 2 case carried a CHST3 mutation, supporting the phenotypic overlap with SDCD. In patient fibroblasts with CANT1 mutations, glycosaminoglycan synthesis was significantly reduced in the presence of β-D-xyloside, suggesting CANT1 plays a role in proteoglycan metabolism. No drug intervention was tested in this study.
A 1996 report described a Brazilian patient with spondyloepimetaphyseal dysplasia with joint laxity (SEMDJL), a rare autosomal recessive condition characterised by dwarfism, articular hypermobility, progressive spinal malalignment, and a propensity to joint dislocation. At that time, the condition had only been described in 20 children of Afrikaans-speaking parents in South Africa. A 1998 report presented three unrelated patients with normal intelligence, striking epiphyseal and metaphyseal changes, joint laxity, and multiple large joint dislocations, particularly incapacitating at the knees. No drug treatments were mentioned in either report.
A 2021 case report described a 49-year-old woman with spondyloepiphyseal dysplasia who underwent total knee arthroplasty for severe osteoarthritis and irreducible congenital dislocation of the patella. Two years after surgery, she reported no pain and walked with elbow crutches. The Hospital for Special Surgery knee score rose from 51 preoperatively to 85 at final follow-up, and postoperative range of motion was 0–115 degrees. This is a single surgical case, not a drug study.
No drug has been tested in a controlled trial for this condition. What is missing is any preclinical or clinical drug repurposing work, funding for basic research into CANT1 and CHST3 pathways, and a trial design that could stratify patients by genotype.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Human Mutation · 2012 · 69 citations · open access
Further delineation of CANT1 phenotypic spectrum and demonstration of its role in proteoglycan synthesis
AbstractDesbuquois dysplasia (DD) is characterized by antenatal and postnatal short stature, multiple dislocations, and advanced carpal ossification. Two forms have been distinguished on the basis of the presence (type 1) or the absence (type 2) of characteristic hand anomalies. We have identified mutations in calcium activated nucleotidase 1 gene (CANT1) in DD type 1. Recently, CANT1 mutations have been reported in the Kim variant of DD, characterized by short metacarpals and elongated phalanges. DD has overlapping features with spondyloepiphyseal dysplasia with congenital joint dislocations (SDCD) due to Carbohydrate (chondroitin 6) Sulfotransferase 3 (CHST3) mutations. We screened CANT1 and CHST3 in 38 DD cases (6 type 1 patients, 1 Kim variant, and 31 type 2 patients) and found CANT1 mutations in all DD type 1 cases, the Kim variant and in one atypical DD type 2 expanding the clinical spectrum of hand anomalies observed with CANT1 mutations. We also identified in one DD type 2 case CHST3 mutation supporting the phenotype overlap with SDCD. To further define function of CANT1, we studied proteoglycan synthesis in CANT1 mutated patient fibroblasts, and found significant reduced GAG synthesis in presence of β-D-xyloside, suggesting that CANT1 plays a role in proteoglycan metabolism.
Journal of Medical Genetics · 1998 · 46 citations · open access
A distinct form of spondyloepimetaphyseal dysplasia with multiple dislocations.
AbstractThree unrelated patients with identical radiological features are presented. Hypotonia was noted at birth and one patient was diagnosed as having congenital fibre type disproportion in the neonatal period. Later muscle biopsies, however, were entirely normal. All patients, now in their teens and twenties, are of normal intelligence, show striking epiphyseal and metaphyseal changes of the long bones, and have joint laxity and multiple dislocations of large joints, which are particularly incapacitating at the knees. These three cases represent a sporadic, previously unreported skeletal dysplasia with spondyloepimetaphyseal distribution and multiple large joint dislocations.
American Journal of Medical Genetics · 1996 · 6 citations
Spondyloepimetaphyseal dysplasia with joint laxity (SEMDJL): A Brazilian case
AbstractThis is a report on a Brazilian patient with spondyloepimetaphyseal dysplasia with joint laxity (SEMDJL; MIM 271640), a rare autosomal recessive skeletal dysplasia characterized by dwarfism, articular hypermobility, progressive intractable spinal malalignment, a typical facies and a propensity to joint dislocation and subluxation. The condition has been described only in 20 children of Afrikaans-speaking parents in South Africa. This is the first report of a non-Afrikaans patient with this genetic entity.
Therapeutics and Clinical Risk Management · 2021 · 3 citations · open access
Total Knee Arthroplasty in Spondyloepiphyseal Dysplasia with Irreducible Congenital Dislocation of the Patella: Case Report and Literature Review
AbstractBACKGROUND: Spondyloepiphyseal dysplasia is the clinical term applied to a group of rare genetic disorders with primary involvement of the vertebrae and epiphyses, predisposing the afflicted individuals toward the premature development of osteoarthritis. There are few reports concerning joint replacement therapy in these patients, particularly describing the role of total hip arthroplasty. In this report, we describe the anatomical and technical aspects of spondyloepiphyseal dysplasia that must be considered during surgical planning and performance of total knee arthroplasty. CASE PRESENTATION: A 49-year old woman with a history of spondyloepiphyseal dysplasia suffered from severe osteoarthritis of the knee and irreducible congenital dislocation of the patella. After careful preoperative evaluations and planning, the knee joint deformity was solved by knee joint replacement with realignment of the extensor mechanism using quadricepsplasty. After 2 years of surgery, the patient showed no pain and was able to walk with the help of elbow crutches. The Hospital for Special Surgery knee score increased from preoperative 51 points to 85 points during the final follow-up. The postoperative range of motion increased to final flexion of 0-115°. CONCLUSION: The advances made so far in the medical care for patients with skeletal dysplasia have improved their overall survival during adulthood. The case report described herein demonstrates the numerous challenges and technical aspects of a successful total knee arthroplasty in cases of spondyloepiphyseal dysplasia, highlighting the need to consider skeletal and soft tissue abnormalities of skeletal dysplasia during the planning and performance of joint replacement surgery.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
